SDG

SDG is a private U.S. biotechnology company focused on bio-nanotechnology and drug-delivery platforms for therapeutic and consumer applications. The company has described its core capabilities as cell-targeting and oral formulation nanotechnology systems, with historical work spanning oral delivery of insulin, interferon, and other protein-based therapies, as well as receptor-targeted delivery of both large- and small-molecule agents. Publicly available sources suggest SDG functions primarily as a platform and enabling-technology company rather than as a late-stage clinical therapeutic developer. Its best-known healthcare relevance appears to be in targeted and oral delivery technologies that have informed diabetes-related programs and related translational work around insulin delivery. The company appears to be small, privately held, and based in Cleveland, Ohio.